The known risks of pancreatitis, gastroparesis, and lean body mass loss are variables to be considered as well. In order to present these drugs with a balance of their pros and cons, the longer-term studies showing cardiovascular benefits are also taken into account. In this review, we examine the health risks of obesity and the overall magnitude of the problem. A discussion of potential therapeutic strategies including dietary, physical activity, bariatric surgery, and pharmacologic therapy are described. GLP-1 receptor agonist drug therapy is a key focus with consideration of the mechanism of action, clinical trials in weight management, and the potential role of the drug category in weight maintenance.
Excess dietary protein, above muscle needs for repair or growth, can be converted to fat by the liver and increase visceral adiposity. 167 Structured strength (resistance) training or mixed training (resistance plus aerobic) programs are well established to help preserve lean mass during weight reduction.62,168 Aerobic activity alone has a smaller effect on preserving lean mass during rapid weight reduction. 168 Retrospective studies of GLP-1 therapy support the role of structured exercise programs, for example, 360 min/week with an emphasis on strength exercises to preserve fat-free mass.
- GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss. There are many different types. And theyre just one part of your treatment plan if you have Type 2 diabetes or obesity.
- By activating GLP-1 peptides, these medications affect body weight in many ways, including inhibiting glucagon and stimulating insulin release, and resulting in an average loss of 5% to 15% of body weight sustainable for at least 12 months.13
This particular example perfectly highlights why Weight Loss Through Glp-1 Therapy And Diet is so captivating.
